Drug
Clostridium butyricum miyairi 588 strain clinical trials
Also written CBM588 and Clostridium butyricum MIYAIRI 588.
- studies test it
- 10
- open now
- 4
- in phase 3
- 1
- first study started
- 2010
Keep track of what changes. Save the clostridium butyricum miyairi 588 strain studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 2
- Phase 3
- 1
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 8
City of Hope Medical Center (4) · Osel, Inc. (2) · China Medical University Hospital (1) · Kaohsiung Medical University (1) · SWOG Cancer Research Network (1) · Huashan Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses clostridium butyricum miyairi 588 strain is read from its arms, and is right about nine times in ten.
Testing it · 10
- Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After SurgeryRecruitingPhase 2City of Hope Medical CenterNCT07037004Written as Clostridium butyricum CBM588 Strain
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441Written as Clostridium butyricum CBM 588 Probiotic Strain
- CBM588 Reduces Colorectal Polyp RecurrenceEnrolling by invitationNot applicableKaohsiung Medical UniversityNCT06855355Written as Clostridium butyricum MIYAIRI 588
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingPhase 1Osel, Inc.NCT06399419Written as CBM588 Capsules
- CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell TransplantActive, not recruitingPhase 1City of Hope Medical CenterNCT03922035Written as Clostridium butyricum CBM 588 Probiotic Strain
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingPhase 1City of Hope Medical CenterNCT05122546Written as Clostridium butyricum CBM 588 Probiotic Strain
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCompletedPhase 1City of Hope Medical CenterNCT03829111Written as Clostridium butyricum CBM 588 Probiotic Strain
- The Effect of Probiotics on Depression Syndrome and Risk Factors of Cardiovascular Disease in Hemodialysis PatientsCompletedPhase 4China Medical University HospitalNCT05724511Written as MIYAIRI 588
- Alterations of Gut Microbiome, Function, and Its Intervention After Defunctioning IleostomyStatus unknownEarly Phase 1Huashan HospitalNCT05759741Written as MIYAIRI 588
- Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile InfectionsWithdrawnPhase 2Osel, Inc.NCT01077245Written as MIYA-BM Fine Granules (CBM588)
Codes
What other systems call clostridium butyricum miyairi 588 strain · ClinicalTrials.gg INT016274
- UNII (FDA) D3C7ZS6A9FCLOSTRIDIUM BUTYRICUM MIYAIRI 588 STRAINOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D3C7ZS6A9F | CLOSTRIDIUM BUTYRICUM MIYAIRI 588 STRAIN | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.